Genesis Therapeutics

Genesis published a technical blog post describing DeCAF (Denoiser Cofolding All-atom Flowmap) and DeCAF-Pearl, presenting it as a flow-map distillation approach for fast all-atom cofolding and reporting throughput and speedup implications for screening and synthetic-data generation.

Genesis published a blog post describing results from evaluating the Pearl system on the OpenBind Consortium benchmark, including reported success-rate figures for zero-shot protein–ligand cofolding settings and discussion of inference-time scaling and physics/AI-based pose ranking as part of the Pearl system.

Incyte and Genesis announced an expanded collaboration to accelerate discovery of novel small molecules for Incyte-selected collaboration targets. Genesis said it will receive $120M upfront consideration (including $80M cash and $40M purchase of equity), plus research funding and milestone/royalty eligibility, with the expanded agreement adding at least five new collaboration targets.

Genesis published a release describing Pearl as a generative 3D foundation model for biomolecular structure prediction, including claims about benchmark and real-world pipeline utility (including reported improvements relative to AlphaFold 3).

Genesis announced an additional equity investment from NVentures and a collaboration with NVIDIA to optimize computational methods for GEMS, describing work to improve efficiency for neural network architectures relevant to drug discovery.

Gilead and Genesis announced a strategic collaboration to discover and develop novel therapies; Genesis’ partners/pipeline page describes this as a 2024 collaboration to deploy GEMS against multiple targets and references upfront consideration tied to three initial targets.